Agenus Inc (NAS:AGEN)
$ 2.81 0.06 (2.18%) Market Cap: 64.93 Mil Enterprise Value: 119.07 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Agenus Inc. - Special Call Transcript

Sep 21, 2020 / 06:18PM GMT
Release Date Price: $91.85 (-9.65%)
Matthew Christopher Phipps
William Blair & Company L.L.C., Research Division - Senior Research Analyst

All right. Hello, everyone. Thank you all for joining. My name is Matt Phipps. I'm a biotech analyst here at William Blair. I do have to first point you all to williamblair.com for a list of disclosures.

But I'm happy today to have both management from Agenus Bio; and Dr. David O'Malley, a professor in the Department of Obstetrics and Gynecology at The Ohio State University, to discuss the really important results presented over the weekend at ESMO combining the PD-1 plus CTLA-4 inhibitor bal/zal combo, at monotherapy and combo in second-line cervical cancer.

So today, we'll kind of review the data, go over some questions both specifically about the data and how this combination could fit into the cervical landscape, also talk about a couple of the other kind of key things being studied in this tumor type and then finish up with more of a kind of corporate look at what's going on.

We do have Dhan Chand here as well, Head of Drug Discovery at Agenus, to chime in for some

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot